Altrinsic Global Advisors LLC Sells 25,213 Shares of BioNTech SE (NASDAQ:BNTX)

Altrinsic Global Advisors LLC trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 3.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 627,493 shares of the company's stock after selling 25,213 shares during the period. BioNTech makes up approximately 3.5% of Altrinsic Global Advisors LLC's holdings, making the stock its 11th largest position. Altrinsic Global Advisors LLC owned approximately 0.26% of BioNTech worth $71,503,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in BNTX. Daiwa Securities Group Inc. boosted its holdings in shares of BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after acquiring an additional 128 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares during the last quarter. Midwest Professional Planners LTD. grew its position in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after purchasing an additional 222 shares during the period. Perigon Wealth Management LLC raised its stake in BioNTech by 3.9% during the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after buying an additional 224 shares during the last quarter. Finally, Atomi Financial Group Inc. lifted its holdings in shares of BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after buying an additional 229 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Trading Up 1.9 %

BNTX traded up $1.97 on Monday, hitting $103.99. The company had a trading volume of 789,920 shares, compared to its average volume of 898,995. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business's fifty day simple moving average is $101.72 and its 200 day simple moving average is $110.54. The company has a market cap of $24.96 billion, a PE ratio of -49.66 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. BioNTech's quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts expect that BioNTech SE will post -3.88 EPS for the current year.

Analysts Set New Price Targets

BNTX has been the subject of a number of recent research reports. BMO Capital Markets boosted their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Morgan Stanley lowered their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Citigroup began coverage on BioNTech in a research report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target for the company. Truist Financial began coverage on BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective on the stock. Finally, HC Wainwright reduced their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.